The Pharma Navigator’s interview with Nanexa CEO David Westberg at BIO 2026 explores how the company is engineering long‑acting injectables with unprecedented precision. Westberg explains that moving from daily or weekly dosing to monthly or quarterly regimens hinges on three factors: drug potency, tight control of the release profile, and injectable volumes that remain clinically practical. He highlights the importance of achieving a low peak‑to‑trough ratio to maintain stable therapeutic levels and reduce side effects — an area where Nanexa’s ALD‑based PharmaShell technology has shown strong validation.

The piece spotlights Nanexa’s recent work with semaglutide, where the company achieved peak‑to‑trough ratios below 1.5 for both once‑monthly and once‑quarterly formulations, outperforming commercial weekly products. Westberg details how Nanexa’s gas‑phase, dry ALD coating protects fragile biologics inside the depot, ensuring that molecules released even on day 75 or 90 remain fully intact. The interview positions PharmaShell as a next‑generation solution for long‑acting biologics, offering controlled release, molecular stability and a viable path to extended‑interval dosing.

Watch the video here.